(Q50650942)

17 March 2018

title

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. (English)

1 reference

17 March 2018

1 reference

1 reference

9

Alex Sparreboom

1 reference

17 March 2018

Jürgen Venitz

7

object named as

Jurgen Venitz

1 reference

17 March 2018

author name string

Milin R Acharya

1

1 reference

17 March 2018

Judith E Karp

2

1 reference

17 March 2018

Edward A Sausville

3

1 reference

17 March 2018

Kyunghwa Hwang

4

1 reference

17 March 2018

Qin Ryan

5

1 reference

17 March 2018

Ivana Gojo

6

1 reference

17 March 2018

William D Figg

8

1 reference

17 March 2018

publication date

1 September 2006

1 reference

17 March 2018

Investigational New Drugs

published in

1 reference

17 March 2018

volume

24

1 reference

17 March 2018

issue

5

1 reference

17 March 2018

page(s)

367-375

1 reference

17 March 2018

https://scigraph.springernature.com/pub.10.1007/s10637-005-5707-6

exact match

0 references

cites work

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-005-5707-6

What is the effect of adjusting epirubicin doses for body surface area?

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-005-5707-6

The impact of obesity and disease on busulfan oral clearance in adults

21 January 2018

1 reference

12 December 2020

A formula to estimate the approximate surface area if height and weight be known. 1916.

1 reference

12 December 2020

Is dose normalization to weight or body surface area useful in adults?

1 reference

12 December 2020

The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

1 reference

12 December 2020

Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?

1 reference

12 December 2020

How to calculate the dose of chemotherapy

1 reference

12 December 2020

Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives

1 reference

12 December 2020

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells

1 reference

12 December 2020

Simplified calculation of body-surface area.

1 reference

12 December 2020

Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry

1 reference

12 December 2020

Histone deacetylase inhibitors and anticancer therapy

1 reference

12 December 2020

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

1 reference

12 December 2020

Lean body mass as a predictor of drug dosage. Implications for drug therapy

1 reference

12 December 2020

Pharmacogenomics of the OATP and OAT families

1 reference

12 December 2020

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors

1 reference

12 December 2020

Dosing strategies for anticancer drugs: the good, the bad and body-surface area

1 reference

12 December 2020

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor

1 reference

12 December 2020

Body surface area as a determinant of pharmacokinetics and drug dosing

1 reference

12 December 2020

MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.

1 reference

12 December 2020

Histone deacetylases and cancer: causes and therapies

1 reference

12 December 2020

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure

1 reference

12 December 2020

Factors Involved in the Pharmacokinetics of COL‐3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies

1 reference

12 December 2020

In vitro metabolism of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl) phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor alpha/gamma agonist. I. Role of cytochrome P450, methyltransferases,

1 reference

12 December 2020

Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel

1 reference

12 December 2020

Overview of recent topics in clinical pharmacology of anticancer agents

1 reference

12 December 2020

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

1 reference

12 December 2020

Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation

1 reference

12 December 2020

Lean body mass, body surface area and epirubicin kinetics

1 reference

12 December 2020

Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs

1 reference

12 December 2020

10.1007/S10637-005-5707-6

Identifiers

DOI

1 reference

17 March 2018

1 reference

17 March 2018